Short Interest in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Declines By 36.1%
by Scott Moore · The Cerbat GemNanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 31,224 shares, a decline of 36.1% from the November 30th total of 48,866 shares. Based on an average daily trading volume, of 33,544 shares, the short-interest ratio is currently 0.9 days. Currently, 0.1% of the shares of the company are sold short. Currently, 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 33,544 shares, the short-interest ratio is currently 0.9 days.
Nanobiotix Trading Down 2.4%
Shares of NASDAQ:NBTX traded down $0.55 during trading on Monday, reaching $22.49. 38,003 shares of the company traded hands, compared to its average volume of 35,781. The firm has a fifty day simple moving average of $21.04 and a 200 day simple moving average of $14.02. Nanobiotix has a 1-year low of $2.82 and a 1-year high of $30.35.
Institutional Investors Weigh In On Nanobiotix
An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. bought a new stake in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,356 shares of the company’s stock, valued at approximately $101,000. Institutional investors and hedge funds own 38.81% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on NBTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Wednesday, October 8th. Wall Street Zen raised Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $11.00.
View Our Latest Stock Report on NBTX
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.
Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.